Nurix Therapeutics (NRIX) Total Liabilities (2019 - 2026)

Nurix Therapeutics (NRIX) has reported Total Liabilities for 8 consecutive years, with $132.9 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Total Liabilities fell 7.67% year-over-year to $132.9 million; the TTM figure through May 2026 stood at $132.9 million (down 7.67% YoY), while the FY2025 annual figure was $149.4 million, up 4.94% from the prior year.
• Total Liabilities retreated to $132.9 million in Q2 2026 per NRIX's latest filing, from $155.2 million in the prior quarter.
• Across five years, Total Liabilities topped out at $155.2 million in Q1 2026 and bottomed at $74.4 million in Q3 2023.
• Historically, Total Liabilities has averaged $129.7 million across 5 years, with a median of $135.4 million in 2024.
• Annual changes were most pronounced in 2023 — Total Liabilities tumbled 36.32% — and 2024, when it soared 83.85%.
• Nurix Therapeutics' Total Liabilities stood at $113.1 million in 2022, then surged by 37.18% to $155.1 million in 2023, then slipped by 8.22% to $142.4 million in 2024, then gained by 4.94% to $149.4 million in 2025, then slipped by 11.03% to $132.9 million in 2026.
• Business Quant data shows NRIX's Total Liabilities at $132.9 million in Q2 2026, $155.2 million in Q1 2026, and $149.4 million in Q4 2025.